{"id":"hepatitis-b-vaccines","safety":{"commonSideEffects":["Injection site pain or soreness","Fatigue","Headache","Mild fever"],"contraindications":["Severe allergic reaction to previous dose or vaccine component","Severe allergic reaction to yeast"]},"_chembl":{"chemblId":"CHEMBL2108512","moleculeType":"Unknown"},"modality":"Biologic","_dailymed":null,"mechanism":{"target":"Hepatitis B surface antigen (HBsAg)","explanation":"The vaccine contains recombinant hepatitis B surface antigen that triggers an immune response. When administered, it prompts the body to produce antibodies against HBsAg without causing disease. These antibodies remain in the bloodstream and provide immunity against future hepatitis B virus exposure.","oneSentence":"Stimulates the immune system to produce antibodies against hepatitis B surface antigen (HBsAg), providing protection against hepatitis B virus infection."},"_scrapedAt":"2026-03-28T00:47:41.676Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122682,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"hepatitis B vaccine (recombinant)","brand":"Engerix-B","company":"GlaxoSmithKline","rationale":"Established recombinant hepatitis B vaccine for prevention"},{"name":"hepatitis B vaccine (recombinant)","brand":"Recombivax HB","company":"Merck","rationale":"Widely used recombinant hepatitis B vaccine"},{"name":"hepatitis A and B vaccine","brand":"Twinrix","company":"GlaxoSmithKline","rationale":"Combination vaccine providing protection against both hepatitis A and B"}],"description":"Hepatitis B vaccines are immunizations designed to prevent infection with the hepatitis B virus (HBV), a serious liver infection that can become chronic and lead to cirrhosis or liver cancer. These vaccines work by stimulating the immune system to produce antibodies against the hepatitis B surface antigen.","indications":{"approved":[{"status":"approved","condition":"Hepatitis B virus infection prevention","patientPopulation":"All age groups including infants, children, and adults"}]},"trialDetails":[{"nctId":"NCT00001971","phase":"","title":"Evaluation of Patients With Liver Disease","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1992-05-27","conditions":"Hepatitis D, Hepatitis C, Hepatitis B","enrollment":8050},{"nctId":"NCT07497594","phase":"NA","title":"ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention","status":"RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2026-02-03","conditions":"Contact With or Exposure to Human Immunodeficiency Virus","enrollment":1500},{"nctId":"NCT07491848","phase":"","title":"Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D","status":"RECRUITING","sponsor":"Research Center of Periodontal-Systemic Interactions","startDate":"2026-02-15","conditions":"HEPATITIS B CHRONIC, Hepatitis D, Periodontitis","enrollment":25},{"nctId":"NCT00001352","phase":"","title":"Fungal Infection Susceptibility","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1993-04-01","conditions":"Cryptococcal Infection, Cryptococcal Pneumonia, Pulmonary Cryptococcosis","enrollment":800},{"nctId":"NCT01581554","phase":"","title":"Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2011-05-18","conditions":"Chronic Hepatitis B e Antigen Positive, Chronic Hepatitis B e Antigen Negative","enrollment":15},{"nctId":"NCT06544863","phase":"","title":"Evaluation of Patient Care Support for Cirrhosis and/or Liver Transplants","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-03-19","conditions":"Cirrhosis","enrollment":3000},{"nctId":"NCT05551273","phase":"PHASE2","title":"Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-05-05","conditions":"Hepatitis B, HIV Infections","enrollment":29},{"nctId":"NCT03394053","phase":"","title":"The Mechanistic Biology of Primary Immunodeficiency Disorders","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-05-30","conditions":"Primary Immunodeficiency Disorders","enrollment":2500},{"nctId":"NCT06357806","phase":"NA","title":"The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-05-17","conditions":"Chronic Hepatitis B","enrollment":45},{"nctId":"NCT06092333","phase":"PHASE2","title":"VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2025-01-31","conditions":"Chronic Hepatitis B","enrollment":50},{"nctId":"NCT06364930","phase":"PHASE4","title":"SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-03-26","conditions":"Chronic Hepatitis B","enrollment":412},{"nctId":"NCT07481032","phase":"NA","title":"Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-04-01","conditions":"Cirrhosis, Liver, Hepatocellular Carcinoma (HCC), HEPATITIS B CHRONIC","enrollment":1034},{"nctId":"NCT07024641","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"GigaGen, Inc.","startDate":"2024-11-13","conditions":"Hepatitis B Virus Infection","enrollment":48},{"nctId":"NCT07471217","phase":"PHASE1","title":"[¹⁴C] Hydronidone Mass Balance Study","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-04-30","conditions":"Chronic Hepatitis B-related Liver Fibrosis","enrollment":8},{"nctId":"NCT07459426","phase":"","title":"Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)","status":"NOT_YET_RECRUITING","sponsor":"Yaşar Bayındır, MD","startDate":"2026-03-15","conditions":"Hepatitis B, Chronic","enrollment":700},{"nctId":"NCT00004850","phase":"","title":"Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"1991-03-15","conditions":"Hepatitis C, Hepatitis B","enrollment":805},{"nctId":"NCT07450651","phase":"","title":"Hepatic and Splenic Microcirculatory Perfusion for Ruling Out High-Risk Varices in Patients With Hepatitis B-Related Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2026-02","conditions":"Hepatitis B Virus Related Cirrhosis, Portal Hypertension Related to Cirrhosis, Esophagogastric Varices","enrollment":150},{"nctId":"NCT07389044","phase":"PHASE1","title":"A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B","status":"RECRUITING","sponsor":"IntegerBio","startDate":"2026-02-20","conditions":"Chronic Hepatitis B Virus Infection","enrollment":90},{"nctId":"NCT03419481","phase":"PHASE2","title":"Pembrolizumab in Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"CCTU","startDate":"2018-04-30","conditions":"HCC","enrollment":30},{"nctId":"NCT02932150","phase":"PHASE2","title":"Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2016-11","conditions":"Chronic Hepatitis B","enrollment":150},{"nctId":"NCT05621304","phase":"","title":"Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study)","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2017-01-03","conditions":"Chronic Hepatitis B Virus (Hbv)","enrollment":274},{"nctId":"NCT07342881","phase":"PHASE1","title":"Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function","status":"RECRUITING","sponsor":"Aligos Therapeutics","startDate":"2026-02-20","conditions":"Chronic Hepatitis B Infection","enrollment":30},{"nctId":"NCT06779058","phase":"","title":"MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B","status":"RECRUITING","sponsor":"Shengjing Hospital","startDate":"2025-01-01","conditions":"Chronic Hepatitis B, Liver Fibrosis","enrollment":600},{"nctId":"NCT04357600","phase":"PHASE1, PHASE2","title":"Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B","status":"ENROLLING_BY_INVITATION","sponsor":"PT. Prodia Stem Cell Indonesia","startDate":"2018-05-17","conditions":"Liver Cirrhoses","enrollment":12},{"nctId":"NCT04496882","phase":"PHASE4","title":"Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-09-09","conditions":"Chronic Hepatitis b, Hepatitis B Reactivation","enrollment":260},{"nctId":"NCT04804072","phase":"NA","title":"INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2021-06-02","conditions":"HIV Infections, Drug Use, Opioid Use","enrollment":447},{"nctId":"NCT03866187","phase":"PHASE1, PHASE2","title":"Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-03-28","conditions":"Hepatitis B, Chronic","enrollment":236},{"nctId":"NCT05705427","phase":"PHASE4","title":"The COMBAT HBV Feasibility Trial","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-08-17","conditions":"Hepatitis B, Vertical Transmission of Infectious Disease","enrollment":317},{"nctId":"NCT07236268","phase":"","title":"Prevalence of HIV and Sexually Transmitted Infections in Migrant Communities in Slovakia","status":"COMPLETED","sponsor":"Comenius University","startDate":"2023-03-15","conditions":"STIs, HIV, Rapid Detection","enrollment":660},{"nctId":"NCT07417553","phase":"PHASE2","title":"A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-03-15","conditions":"Chronic Hepatitis B-related Liver Fibrosis","enrollment":150},{"nctId":"NCT07413549","phase":"PHASE1, PHASE2","title":"Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis","status":"RECRUITING","sponsor":"Beijing Tuohua Weiye Biotechnology Co., Ltd.","startDate":"2025-02-25","conditions":"Decompensated Hepatitis B Cirrhosis","enrollment":76},{"nctId":"NCT07412236","phase":"PHASE3","title":"A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-01-30","conditions":"Liver Fibrosis, Liver Fibrosis in Chronic Hepatitis B","enrollment":1208},{"nctId":"NCT05390424","phase":"NA","title":"Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2022-12-02","conditions":"Hepatitis B, Hepatitis C, AIDS","enrollment":500},{"nctId":"NCT07394309","phase":"PHASE1","title":"Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-02-15","conditions":"Liver Fibrosis","enrollment":30},{"nctId":"NCT04431245","phase":"","title":"Stopping Antiviral Treatment in Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2021-06-01","conditions":"Chronic Hepatitis b","enrollment":54},{"nctId":"NCT06507605","phase":"PHASE1","title":"Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2024-08-30","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":240},{"nctId":"NCT05612581","phase":"PHASE1, PHASE2","title":"A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Vir Biotechnology, Inc.","startDate":"2023-05-10","conditions":"Hepatitis B, Chronic","enrollment":33},{"nctId":"NCT06963710","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)","status":"RECRUITING","sponsor":"Aligos Therapeutics","startDate":"2025-07-15","conditions":"Chronic Hepatitis B Infection","enrollment":200},{"nctId":"NCT07388979","phase":"","title":"MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo","status":"NOT_YET_RECRUITING","sponsor":"Gardiens de Vies","startDate":"2026-03-01","conditions":"HIV - Human Immunodeficiency Virus, HBV (Hepatitis B Virus), Hepatitis C Virus (HCV)","enrollment":7500},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT06497504","phase":"PHASE2","title":"Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-09-17","conditions":"Hepatitis B","enrollment":157},{"nctId":"NCT07160244","phase":"PHASE3","title":"BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-25","conditions":"Healthy","enrollment":6000},{"nctId":"NCT06082336","phase":"NA","title":"Prospective Clinical Performance Evaluation of the In-Vitro Diagnostics Medical Device MaGIA IBC for the CombIned screENing of HIV, Hepatitis B and Hepatitis C","status":"RECRUITING","sponsor":"MagIA Diagnostics","startDate":"2024-09-16","conditions":"Combined Point of Care Diagnostic of HIV, HBV and HCV","enrollment":252},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT07170748","phase":"","title":"Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis)","status":"RECRUITING","sponsor":"MagIA Diagnostics","startDate":"2025-07-29","conditions":"Multiplex Testing of HIV, HBV, HCV and Syphilis, HIV, HBV","enrollment":2950},{"nctId":"NCT05856890","phase":"PHASE1","title":"HepB mAb19 in Individuals With Chronic Hepatitis B Infection","status":"RECRUITING","sponsor":"Rockefeller University","startDate":"2023-08-07","conditions":"Hepatitis b Virus, Hepatitis B","enrollment":37},{"nctId":"NCT06663436","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Diarrhoea","enrollment":200},{"nctId":"NCT01651403","phase":"PHASE3","title":"Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2012-12-06","conditions":"Chronic Hepatitis B","enrollment":90},{"nctId":"NCT05147090","phase":"PHASE4","title":"Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2022-01-02","conditions":"Chronic Hepatitis b, NAFLD, Cirrhosis","enrollment":106},{"nctId":"NCT07200193","phase":"PHASE1, PHASE2","title":"A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B","status":"RECRUITING","sponsor":"nChroma Bio","startDate":"2025-12-22","conditions":"Chronic Hepaititis B","enrollment":66},{"nctId":"NCT07370207","phase":"PHASE2","title":"Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region","status":"NOT_YET_RECRUITING","sponsor":"AusperBio Therapeutics Inc.","startDate":"2026-02-02","conditions":"Hepatitis B, Chronic","enrollment":84},{"nctId":"NCT06644417","phase":"PHASE2","title":"Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-11-14","conditions":"HBV Infection With LLV","enrollment":122},{"nctId":"NCT02750202","phase":"PHASE3","title":"Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts","status":"COMPLETED","sponsor":"University of Pretoria","startDate":"2018-07-01","conditions":"Genital Warts","enrollment":52},{"nctId":"NCT05770895","phase":"PHASE1","title":"Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2023-04-03","conditions":"Chronic Hepatitis B","enrollment":83},{"nctId":"NCT07364448","phase":"PHASE2","title":"A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-01-30","conditions":"Chronic Hepatitis B With Hepatic Fibrosis","enrollment":200},{"nctId":"NCT07090759","phase":"PHASE3","title":"To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment","status":"RECRUITING","sponsor":"Fujian Akeylink Biotechnology Co., Ltd.","startDate":"2025-07-24","conditions":"Chronic Hepatitis b","enrollment":526},{"nctId":"NCT01298037","phase":"","title":"HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2011-02-01","conditions":"Hepatitis B","enrollment":201},{"nctId":"NCT05763576","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2023-04-28","conditions":"Chronic Hepatitis B","enrollment":60},{"nctId":"NCT01796457","phase":"","title":"HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2013-03","conditions":"Hepatitis B","enrollment":40},{"nctId":"NCT06786429","phase":"PHASE4","title":"Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.","status":"NOT_YET_RECRUITING","sponsor":"Eunice Dube","startDate":"2026-08-30","conditions":"Hepatitis B, Human Papilloma Virus, Gall Stones (& [Calculus - Gall Bladder])","enrollment":1800},{"nctId":"NCT03149627","phase":"","title":"Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2017-06-07","conditions":"HBV, Alcoholic Hepatitis, Liver Fibroses","enrollment":5003},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT04294433","phase":"PHASE4","title":"Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children","status":"COMPLETED","sponsor":"Laval University","startDate":"2018-06-11","conditions":"Hepatitis B","enrollment":431},{"nctId":"NCT07317687","phase":"","title":"Rapid HIV, Hep C, and Syphilis Screening in a Rural Street Medicine Clinic","status":"NOT_YET_RECRUITING","sponsor":"West Virginia University","startDate":"2026-01","conditions":"HIV Testing, HEPATITIS C (HCV), Syphilis","enrollment":200},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT07345624","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":"Hepatitis B Virus Infection, Children, Chronic Hepatitis B","enrollment":80},{"nctId":"NCT07345611","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":"Hepatitis B Virus Infection, Children, Chronic Hepatitis B","enrollment":60},{"nctId":"NCT07346508","phase":"NA","title":"Project SPEED - Streamlined Protocol for Early Engagement and Delivery of HIV Prevention With Long-acting Injectable Cabotegravir: A Nurse-driven Protocol","status":"NOT_YET_RECRUITING","sponsor":"KC Care Health Center","startDate":"2026-04-01","conditions":"HIV (Human Immunodeficiency Virus)","enrollment":250},{"nctId":"NCT07343778","phase":"PHASE3","title":"A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-01-20","conditions":"Chronic Hepatitis B With Hepatic Fibrosis","enrollment":300},{"nctId":"NCT05561673","phase":"PHASE1","title":"A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-04","conditions":"Hepatitis B","enrollment":122},{"nctId":"NCT07135349","phase":"PHASE2","title":"A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Argo Biopharmaceutical Co., Ltd.","startDate":"2025-09-02","conditions":"Chronic Hepatitis B","enrollment":209},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Hepatitis B","enrollment":58},{"nctId":"NCT02738008","phase":"PHASE2","title":"Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-03","conditions":"Hepatitis B","enrollment":12},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT02065336","phase":"PHASE2","title":"A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2014-03","conditions":"Hepatitis B, Chronic","enrollment":58},{"nctId":"NCT04327440","phase":"","title":"RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi","status":"COMPLETED","sponsor":"Michigan State University","startDate":"2020-02-04","conditions":"Malaria, Malaria Vaccine, Insecticide-treated Bednets","enrollment":1691},{"nctId":"NCT02604212","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-11","conditions":"Hepatitis B","enrollment":32},{"nctId":"NCT02797522","phase":"PHASE1","title":"A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-06","conditions":"Hepatitis B","enrollment":47},{"nctId":"NCT07328711","phase":"EARLY_PHASE1","title":"Immunomodulatory Therapy and Predictors of Clinical Cure in Chronic Hepatitis B","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-01-01","conditions":"Chronic Hepaititis B","enrollment":132},{"nctId":"NCT06624176","phase":"NA","title":"ShotBlocker During Intramuscular Injection Randomized Control Trial","status":"RECRUITING","sponsor":"Lauren Fortier","startDate":"2024-01-10","conditions":"Neonatal Pain","enrollment":200},{"nctId":"NCT06671093","phase":"PHASE1","title":"Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B","status":"RECRUITING","sponsor":"Tune Therapeutics, Inc.","startDate":"2024-11-29","conditions":"Chronic Hep B, Chronic Hepatitis b, Chronic Hepatitis","enrollment":36},{"nctId":"NCT07320716","phase":"PHASE2","title":"Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-01-02","conditions":"Diarrhoea","enrollment":528},{"nctId":"NCT05276297","phase":"PHASE2","title":"A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-03-22","conditions":"Hepatitis B, Chronic","enrollment":174},{"nctId":"NCT07307586","phase":"PHASE3","title":"A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B","status":"RECRUITING","sponsor":"Zhigang Ren","startDate":"2025-09-01","conditions":"Chronic Hepatitis B, Azvudine","enrollment":120},{"nctId":"NCT06993480","phase":"PHASE2","title":"A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)","status":"RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2025-06-18","conditions":"Chronic Hepatitis B","enrollment":30},{"nctId":"NCT02349126","phase":"PHASE2","title":"Study of ARC-520 in Patient With Chronic Hepatitis B Virus","status":"WITHDRAWN","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-02","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT06347588","phase":"","title":"Risk of Reactivation of Occult Hepatitis B in Cancer Patients During Immunotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2022-06-06","conditions":"Occult Hepatitis B Infection in Cancer Patients","enrollment":60},{"nctId":"NCT07246889","phase":"PHASE3","title":"Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2025-08-12","conditions":"Chronic Hepatitis B","enrollment":577},{"nctId":"NCT06901362","phase":"","title":"Seroprevalence and Vaccination Rate of Hepatitis B Virus and Varicella-zoster Virus Among Medical Students Under Immunizing Program","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2025-04-01","conditions":"Healthy, Healthy Adult","enrollment":401},{"nctId":"NCT07295873","phase":"PHASE1","title":"Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2025-12-30","conditions":"Chronic Hepatitis B Liver Fibrosis, DDI (Drug-Drug Interaction)","enrollment":64},{"nctId":"NCT05127187","phase":"NA","title":"Estimation of the Prevalence of HIV, Hepatitis C and Hepatitis B Infection Among Detainees in the Nîmes Administrative Detention Center","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2022-02-08","conditions":"HIV Infections, Hepatitis C, Hepatitis B","enrollment":350},{"nctId":"NCT06494579","phase":"PHASE1, PHASE2","title":"Lamivudine for Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Marron","startDate":"2024-09-26","conditions":"Relapsed/Refractory Solid Tumors","enrollment":12},{"nctId":"NCT07085377","phase":"NA","title":"Autonomous Methadone Delivery System by Nurses","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-12-08","conditions":"Opioid Use Disorder (OUD), Addictology","enrollment":182},{"nctId":"NCT07282249","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in the Treatment of Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Grand Theravac Life Sciences (Nanjing) Co., Ltd.","startDate":"2025-12-31","conditions":"Chronic hepatitisB","enrollment":630},{"nctId":"NCT01198860","phase":"","title":"Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B","status":"APPROVED_FOR_MARKETING","sponsor":"Nguyen Thi Trieu, MD","startDate":"","conditions":"CHRONIC HEPATITIS B","enrollment":""},{"nctId":"NCT07031219","phase":"NA","title":"HIV/HBV/HCV Triple Screening in Primary Care","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02-15","conditions":"HIV, HBV (Hepatitis B Virus), HCV","enrollment":50},{"nctId":"NCT04674462","phase":"PHASE4","title":"Understanding Poor Vaccine Responses to Hepatitis B Vaccination","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-07-07","conditions":"Vaccine Reaction","enrollment":101},{"nctId":"NCT05630807","phase":"PHASE3","title":"Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-12-07","conditions":"Chronic Hepatitis B, Hepatitis B, Chronic","enrollment":981},{"nctId":"NCT06909188","phase":"","title":"The Study of Association of Helicobacter Infections in Biliary Tract Cancers","status":"RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-03-31","conditions":"Biliary Tract Cancer","enrollment":250},{"nctId":"NCT05630820","phase":"PHASE3","title":"Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-12-06","conditions":"Chronic Hepatitis B, Hepatitis B, Chronic","enrollment":857}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":781,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"hepatitis B vaccines","genericName":"hepatitis B vaccines","companyName":"National Heart, Lung, and Blood Institute (NHLBI)","companyId":"national-heart-lung-and-blood-institute-nhlbi","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}